期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/jpm12020185
关键词
denosumab; adherence; mortality; renal function; chronic kidney disease
资金
- Ministry of Science and Technology, Taiwan [MOST 109-2314-B-037-088]
- Kaohsiung Municipal Ta-Tung Hospital, Taiwan [kmtth-109-R006]
- Kaohsiung Medical University Hospital, Taiwan [KMUH-DK(B)110003-1, KMUH110-0M13, KMUH110-0M12, KMUH109-9R16, KMUH108-8M11, KMUH106-6T03, KMU-DK(B)110003, KMU-Q108024]
- [KMU-TC108B04]
- [KMUTC111IFSP0]
This study aimed to investigate the safety, treatment adherence, renal function effect, and mortality of denosumab in CKD patients. The results showed that high adherence users had better renal function and no decline in renal function. The all-cause mortality rate was lower in high adherence users compared to low adherence users in both the overall cohort and CKD subcohort.
Denosumab is approved for osteoporosis treatment in subjects with and without chronic kidney disease (CKD). Confirmation is required for its safety, treatment adherence, renal function effect, and mortality in patients with CKD. A retrospective cohort study was conducted to compare new users of denosumab in terms of their two-year drug adherence in all participants (overall cohort) and CKD participants (CKD subcohort), which was defined as baseline estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m(2). The eGFR was calculated using the 2021 CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. We defined high adherence (HA) users as receiving three or four doses and low adherence (LA) users as receiving one or two doses. All-cause mortality was analyzed using Kaplan-Meier curves and Cox regression models. In total, there were 1142 subjects in the overall cohort and 500 subjects in the CKD subcohort. HA users had better renal function status at baseline than LD users in the overall cohort. A decline in renal function was only observed among LD users in the overall cohort. In the CKD subcohort, no baseline renal function difference or renal function decline was demonstrated. The all-cause mortality rate of HA users was lower than LA users in both the overall cohort and CKD. A randomized control trial is warranted to target this unique population to confirm our observations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据